AZTO Stock Overview
A life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ArcticZymes Technologies ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 65.30 |
| 52 Week High | NOK 79.00 |
| 52 Week Low | NOK 65.30 |
| Beta | 1.13 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -10.12% |
| 3 Year Change | 824.93% |
| 5 Year Change | 939.81% |
| Change since IPO | 451.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| AZTO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -0.6% |
| 1Y | -10.1% | -24.1% | 3.1% |
Return vs Industry: AZTO exceeded the UK Biotechs industry which returned -28.7% over the past year.
Return vs Market: AZTO underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| AZTO volatility | |
|---|---|
| AZTO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AZTO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AZTO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 60 | Jethro Holter | www.arcticzymes.com |
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally.
ArcticZymes Technologies ASA Fundamentals Summary
| AZTO fundamental statistics | |
|---|---|
| Market cap | NOK 2.08b |
| Earnings (TTM) | NOK 33.11m |
| Revenue (TTM) | NOK 137.66m |
62.9x
P/E Ratio15.1x
P/S RatioIs AZTO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZTO income statement (TTM) | |
|---|---|
| Revenue | NOK 137.66m |
| Cost of Revenue | NOK 5.18m |
| Gross Profit | NOK 132.48m |
| Other Expenses | NOK 99.37m |
| Earnings | NOK 33.11m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 02, 2023
| Earnings per share (EPS) | 0.65 |
| Gross Margin | 96.24% |
| Net Profit Margin | 24.05% |
| Debt/Equity Ratio | 0% |
How did AZTO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/21 09:33 |
| End of Day Share Price | 2022/11/24 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ArcticZymes Technologies ASA is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hans Bohn | Beringer Finance AB |
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |
| Espen Jørgensen | DNB Markets |